key: cord-0878659-qkc5edv9
authors: Zaidman, Daniel; Gehrtz, Paul; Filep, Mihajlo; Fearon, Daren; Prilusky, Jaime; Duberstein, Shirly; Cohen, Galit; Owen, David; Resnick, Efrat; Strain-Damerell, Claire; Lukacik, Petra; Barr, Haim; Walsh, Martin A.; von Delft, Frank; London, Nir
title: An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor
date: 2020-09-21
journal: bioRxiv
DOI: 10.1101/2020.09.21.299776
sha: 2269d8331cbb24a7e46cb79c3a3d463a57f48962
doc_id: 878659
cord_uid: qkc5edv9

Designing covalent inhibitors is a task of increasing importance in drug discovery. Efficiently designing irreversible inhibitors, though, remains challenging. Here, we present covalentizer, a computational pipeline for creating irreversible inhibitors based on complex structures of targets with known reversible binders. For each ligand, we create a custom-made focused library of covalent analogs. We use covalent docking, to dock these tailored covalent libraries and to find those that can bind covalently to a nearby cysteine while keeping some of the main interactions of the original molecule. We found ~11,000 cysteines in close proximity to a ligand across 8,386 protein-ligand complexes in the PDB. Of these, the protocol identified 1,553 structures with covalent predictions. In prospective evaluation against a panel of kinases, five out of nine predicted covalent inhibitors showed IC50 between 155 nM - 4.2 μM. Application of the protocol to an existing SARS-CoV-1 Mpro reversible inhibitor led to a new acrylamide inhibitor series with low micromolar IC50 against SARS-CoV-2 Mpro. The docking prediction was validated by 11 co-crystal structures. This is a promising lead series for COVID-19 antivirals. Together these examples hint at the vast number of covalent inhibitors accessible through our protocol.

Covalent irreversible inhibitors have become increasingly popular over the last decade as 45 chemical probes and drugs. Most often these inhibitors target a cysteine residue to form the 46 covalent bond. Several rationally-designed irreversible inhibitors targeting cysteines were 47 approved by the FDA in recent years, with notable examples such as Ibrutinib 1 , Afatinib 2 and 48 Osimertinib 3 . Irreversible binding offers a variety of advantages, including prolonged residence 49 time 4 and an ability to compete with high-affinity natural substrates 5-7 . Another important 50 advantage of covalent inhibitors is their improved selectivity when targeting non-conserved 51 cysteine residues 8, 9 . Moreover, covalent binding can enable targeting of especially challenging 52 targets such as the G12C oncogenic K-Ras mutation 10-12 . 53 Historically, most covalent inhibitors were designed by the addition of an electrophile to 54 an already known reversible inhibitor that suitably binds next to a cysteine residue 13-18 . More Furthermore, the "covalentized" (derivative containing the electrophile) version of the reversible 68 inhibitor should be synthetically accessible. Therefore, tools that would enable to address this 69 design problem algorithmically, would significantly simplify covalent inhibitor design and has the 70 potential to discover many potent covalent binders for a large variety of targets. 71 Computational approaches to address this challenge are scarce. DUckCov 29 a covalent 72 virtual screening method, begins with non-covalent docking of a library of covalent compounds, 73 while using pharmacophoric constraints for hydrogen bonds, as well as for the covalent warhead. 74 This is followed by covalent docking of the ligands with the strongest non-covalent affinities. 75 CovaDOTS 33 uses a set of synthetic schemes and available building blocks, to create covalent 76 analogs of existing non-covalent ligands, but was only assessed retrospectively. Cov_FB3D 34 77 constructs de novo covalent ligands and was retrospectively assessed on recapitulation on known 78 covalent inhibitors. 79 Here we present a computational pipeline to identify potential existing reversible binders 80 for covalentization (creation of a covalent analog). Given a complex structure or model of a ligand 81 in the vicinity of a cysteine residue, we elaborate the ligand or its substructures with various 82 electrophiles. This ad hoc library of covalent analogs is covalently docked to the target protein and 83 the original (non-covalent) structure is used as a filter to identify high-confidence covalent 84 candidates. We applied this protocol -covalentizer -to the entire PDB to identify thousands of 85 potential candidates amenable for irreversible inhibition, and made both the protocol and the 86 database of pre-computed candidates publicly available to the community 87 (https://covalentizer.weizmann.ac.il). We have prospectively synthesized and tested several 88 predictions of various covalent kinase inhibitors proposed by the protocol and succeeded in five 89 out of nine designs with IC50's of 155 nM -4.2 µM.

In early February 2020, the COVID-19 pandemic started to spread globally 35,36 . We turned 91 to the pre-compiled database of covalentizer results, to look for possible candidate inhibitors for 

The covalentizer pipeline 104 105

For a given complex structure with a reversible ligand in the vicinity of a target cysteine 106 residue, the pipeline ( Fig. 1 ) comprises four consecutive steps: fragmentation, electrophile 107 diversification, covalent docking and RMSD filtering. 

The protocol comprises four consecutive steps. A. Fragmentation: the molecule is broken and divided into fragments 112 (red arrows) using synthetically accessible bonds 38 . Murcko scaffolds 39 of the fragments (blue arrows) are also added 113 to the list of fragments. B. Electrophilic diversification: for each substructure, a library of potential electrophilic 114 analogs is generated, a few hundred compounds in size. We used four kinds of nitrogen-based electrophiles ranging 115 in reactivity: vinyl sulfones, chloroacetamides, acrylamides and propynamides. We also considered various linkers 116 between the fragment and the electrophile. C. Docking: The target structure is then docked against its appropriate 

A. Fragmentation: In this step, the ligand is broken-down and divided into two parts via 124 synthetically accessible bonds 38 . Doing this recursively, results in a list of substructures (Fig. 1A) .

For each substructure, we augment the list with its corresponding Murcko scaffold 39 (the naked 126 ring system, without any decoration) to allow more exit vectors from which the electrophile can 127 be added next. The motivation for this fragmentation step is three-fold. First, as mentioned, B. Electrophile diversification: For each substructure or scaffold, we generate a library of potential 141 electrophilic analogs, typically resulting in a few hundred analogs (Fig. 1B) . We consider four 142 kinds of electrophiles ranging in reactivity: vinyl sulfonamides, chloroacetamides, acrylamides 143 and propynamides, that can all be installed in one step onto a free amine. We add these 144 electrophiles to the substructures using simple connection rules which, however, do not guarantee 145 synthetic accessibility (see methods section for more details). We also consider various linkers 146 between the fragment and the electrophile. In our application below, we considered either a 147 methylene linker or various di-amine linkers (Supp. Fig. 1 ).

C. Covalent docking: The structure of the complex is prepared for docking, using all available 150 cysteine rotamers. We use DOCKovalent 26 to dock the electrophile library we described above To benchmark the pipeline, we wanted to test whether it is able to find known covalent inhibitors, 166 given only their reversible part as input. To achieve this, we used the kinase subset of a recently Encouraged by the results in recapitulating known covalent kinase inhibitors we aimed to 184 apply our protocol to the entire PDB. We started from the set of all the protein-small molecule X- The ligand that is most abundant in this database is Flavin-Adenine Dinucleotide occurring in 504 198 structures, whereas 3,058 ligands (83% of the compounds) occur only in a single structure. The 199 most common ligands were nucleotide or nucleotide-like molecules.

After running the aforementioned algorithm against the ~8,400 structures that passed our 201 filtering ( Fig 3A) , 1,553 structures produced at least one candidate below the 1.5 Å RMSD cutoff.

These structures represent roughly 380 proteins (representative set at 95% sequence identity). 

and contained a small molecule of at least 300 Da. This threshold was set to ensure some minimal initial fit/binding 214 affinity to the target, as well as to filter out non-ligand small molecules like crystallization reagents. We used a pymol 215 based script to filter only the structures in which at least one ligand atom is < 6 Å away from the sulfur atom of a 216 cysteine residue. This cysteine also has to be free (no disulfide or other covalent modifications). After running the 217 covalentizer protocol and filtering only for results with < 1.5 Å RMSD of the maximal common substructure (MCS) 218 between the reversible ligand and the covalent analog generated by covalentizer, there were 1,553 structures for which 219 at least one such prediction was obtained. B. The top 1% of results have an RMSD under 0.5 Å. 23% are between 0.5 220 Å and 1 Å, and 76% are between 1 Å and 1.5 Å. C. The distribution of the four electrophiles used is balanced, with 221 29% chloroacetamides, 27% acrylamides, 24% vinylsulfones, and 20% propynamides.

Exploring additional linkers 224 225 As mentioned above, the entire database was processed using direct attachments of the 226 electrophiles to atoms of the sub-structures, as well as with a methylene linker. The use of longer Fig. 1 ). Since including all of these 232 linkers increases the computational demands of the pipeline, we restricted its application to the 233 subset of liganded kinase structures in the PDB. Since these linkers can enable ligands to reach 234 further cysteines at extended distances, the search criteria was extended to a distance of up to 10 235 Å from the ligand (instead of 6 Å, previously). repetitions for 1 and 2 in Supp. Fig. 3 ). Each compound was tested against its corresponding target kinase. C.

Deconvoluted mass spectra obtained by intact protein LC/MS of recombinant ERK2 (2 µM) incubated with equimolar Fig. 5A ). We re-synthesized and tested racemic 284 ML188 against SARS-CoV-2 M pro which showed an IC50 of 3.14 µM (Supp. Fig. 4A ), similar to 285 what has been reported for SARS-CoV-1. ML188 was synthesized using the Ugi four-component 286 reaction (4-CR), and the covalent prediction was easily accessible by replacing one reactant (2-287 furoic acid to acrylic acid) to give 10, synthesized and isolated as the racemate (Fig. 5D) . We 288 initially assessed irreversible binding of 10 towards recombinant SARS-CoV-2 M pro using intact 289 protein mass spectrometry (2 µM protein, 1.5 h incubation with electrophile at 25 °C; Fig. 5F ).

The expected adduct was detected with 19% labeling at 2 µM compound, and up to 88% labeling 291 at 200 µM compound (Fig. 5F ). Supp. Fig. 7,8) , exploring all three components of the Ugi reaction while keeping the acrylamide 307 fixed. We explored a variety of replacements for the initial p-tert-butylphenyl motif protruding 308 into the S2 pocket (Fig. 5) , most of them did not result in improved potency (Supp. Fig. 7C ).

Similarly, independent optimization of binding to the S1 pocket only led to the identification of fragments were able to bind in these pockets 47 . In this case, we exhaustively synthesized analogs 317 of 10, using 34 available isocyanides. Starting from 10, simple alkyl chain extension resulted in 318 compounds with improved potency (Fig. 5D ). In particular compound 11, harboring a 319 phenethylamide motif, was particularly potent with an IC50 of 2.95 µM (Fig. 5G) and Kinact/Ki of 320 18.4 M -1 s -1 (Supp. Fig. 6 ). 

It appears that relief of steric strain around the amide nitrogen also plays a part, since 337 change to a methyl amide (in 12, relative to 10) also resulted in increased potency. Opposed to our 338 initial assumption of independent optimization of S1-3 pocket binding, the combination of 

A main advantage of our work is the wide exploration of X-ray structures which produced 362 an extensive list of candidates waiting to be explored. This allowed us to quickly find a promising 363 lead series against SARS-CoV-2 M pro . This prediction, which was based on a historic non-covalent 364 SARS-CoV-1 M pro inhibitor 45 was pre-calculated, and ready for synthesis at a moment's notice. 365 We have made thousands of such predictions available through a public website However, as we saw for both ERK2 (1 vs. 5) and M pro (10 vs. 11), improving reversible 392 recognition is able to improve potency, and even to surpass the parent compound in the case of 11. 393 For this series we believe that further structure-based optimization of binding to the S3 pocket, 394 including H-bonding to Glu166 and chiral separation of the active enantiomer can pave the way 395 for sub-micromolar Ugi-type covalent M pro inhibitors. Thus, in many cases where irreversible 396 binding is needed our protocol can provide a promising starting point for optimization. The docking software also ignores the intrinsic reactivity of the proposed designs. It is 407 interesting to note in this regard the similar activity of a methylene-chloroacetamide (1), compared 408 to its acrylamide analog (6). Such electrophile replacements can be very useful in rational design 409 of irreversible inhibitors, especially if they prove to work across various scaffolds. Geometrically, 410 the additional methylene before the chloroacetamide makes the distance from the ring to the thiol 411 similar to that of the acrylamide (Supp. Fig. 2) . In terms of reactivity, however, the acrylamide, 

Many additional designs remain to be discovered beyond the more than 1,500 we made 420 available through the covalentizer server. New electrophiles and linkers which will enable new 421 geometric trajectories between the cysteine and the molecule, can considerably expand the design 422 space. We tested this idea computationally using a library of linkers curated from the literature 423 (Supp . Fig 1) , on a subset of kinases from our database, showing an increase in the number of 424 structures that can be covalentized. New covalent 'warheads', including reversible covalent 425 warheads, such as cyanoacrylamides 60 , and clorofluoroacetamides 61 become available, both for 426 cysteine residues 62 , but also for other amino acids 63-65 . These can be incorporated with little effort 427 into the covalentizer pipeline. Since cysteine is one of the least abundant natural amino acids, 428 additional covalent chemistries will significantly expand the number of ligands that can be 429 potentially addressed.

In summary, we show that using covalent docking we were able to make irreversible 432 analogs of ligands for which a complex structure is available. We made our discoveries public in 433 the form of a database of the results we obtained by running our protocol on the entire PDB which 434 is automatically updated weekly with newly released entries, as well as a web-tool for applying 435 the protocol on new targets given by users. Using the protocol, we discovered new covalent kinase 436 inhibitors and optimised a potent covalent COVID-19 protease inhibitor, with a low-cost, modular 437 and fast synthesis. We hope our results will encourage researchers to apply covalent inhibitors for 438 a wide range of targets. rotamers for the cysteine residue were generated with pymol based scripts. We used RDKit to filter 478 only for results with a MCS that has an RMSD of less than 1.5 Å to the original ligand.

Computational optimisation of the M pro inhibitor 481 We used the RDKit reaction functionalities, as well as OpenBabel Mobile solution A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in 506 acetonitrile. The run flow was 0.4 mL/min with gradient 20% B for 4 min, increasing linearly to 507 60% B for 2 min, holding at 60% B for 0.5 min, changing to 0% B in 0.5 min, and holding at 0% 508 for 1 min. The mass data were collected on a Waters SQD2 detector with an m/z range of Kinase activity assays 516 Biochemical Kinase inhibition assays were carried out at Nanosyn, Santa Clara. Test 517 compounds were diluted in 100% DMSO using 3-fold dilution steps. Final compound 518 concentration in assay ranged from 10 µM to 0.0565 nM. Compounds were tested in a single well 519 for each dilution, and the final concentration of DMSO in all assays was kept at 1%. Reference compound, Staurosporine, was tested in an identical manner. Compounds were preincubated in 521 25C for 2 hours before the measurements, and the kinase reactions were then performed for an 522 additional 3 hours. For ERK2, the kinase concentration was 0.25-0.35 nM, the ATP concentration 523 was 25 µM. For MELK, the kinase concentration was 0.06 nM, the ATP concentration was 30 524 µM. For VEGFR2, the kinase concentration was 0.25 nM, the ATP concentration was 80 µM. For 525 GSK3B, the kinase concentration was 0.09 nM, the ATP concentration was 10 µM. For FGFR4, 526 the kinase concentration was 0.17 nM, the ATP concentration was 250 µM.

Biochemical M pro inhibition assay 529 Compounds were seeded into assay-ready plates (Greiner 384 low volume 784900) using 530 an Echo 555 acoustic dispenser, and DMSO was back-filled for a uniform concentration in assay 531 plates (maximum 1%). Reagents for M pro assay were dispensed into the assay plate in 10 µl 

Bruton tyrosine kinase inhibitor ibrutinib

Phase III study of afatinib or cisplatin plus pemetrexed in patients with 564 metastatic lung adenocarcinoma with EGFR mutations

Association Between Plasma Genotyping and Outcomes of Treatment 567

With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

Prolonged and tunable residence time using reversible covalent 570 kinase inhibitors

Structure-based design of targeted covalent inhibitors

Structural insights into how irreversible inhibitors can overcome drug 574 resistance in EGFR

The T790M mutation in EGFR kinase causes drug resistance by increasing 576 the affinity for ATP

Structural bioinformatics-based 580 design of selective, irreversible kinase inhibitors

Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and 582

Accelerate Nucleotide Exchange

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour 586 immunity

Synthesis and Characterization of Covalent 588 KDM5 Inhibitors

Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective 593

Covalent Inhibitor of Bruton's Tyrosine Kinase

Covalent-allosteric kinase inhibitors

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of 597

Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Structure-Guided Design of Highly Selective and Potent Covalent 600 Inhibitors of ERK1/2

Proteome-wide covalent ligand discovery in native biological systems. 602

Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening

Fragment-Based Covalent Ligand Screening Enables Rapid Discovery 606 of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP

A fragment-based method to discover irreversible 609 covalent inhibitors of cysteine proteases

A Small Molecule That Switches a Ubiquitin Ligase From a 611

Processive to a Distributive Enzymatic Mechanism

High-Throughput Kinetic Analysis for Target-Directed Covalent 614

Ligand and Target Discovery by Fragment-Based Screening in Human 616 Cells

Covalent docking of large libraries for the discovery of chemical probes

Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor

Structure-based 622 virtual screening approach for discovery of covalently bound ligands

DUckCov: a Dynamic Undocking-Based Virtual Screening Protocol for 625

Docking Tools

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3

Inhibitors with Activity toward Resistance-Conferring Mutations

Discovery of covalent enzyme inhibitors using virtual docking of 632 covalent fragments

CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors 634 Using a Linking Strategy

Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-636

A Novel Coronavirus from Patients with Pneumonia in China

A new coronavirus associated with human respiratory disease in China

Discovery, Synthesis, And Structure-Based Optimization of a Series ofN-643 (tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent 644

Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus

RECAP--retrosynthetic 647 combinatorial analysis procedure: a powerful new technique for identifying privileged 648 molecular fragments with useful applications in combinatorial chemistry

The properties of known drugs. 1. Molecular frameworks

Kinase 3 Selective Covalent Inhibitor

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective

Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological 656

Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-658 (3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide 659 (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow 660

Kinase in the X Chromosome (BMX) Kinase Inhibitor

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-663

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Discovery, synthesis, and structure-based optimization of a series of N-(tert-667 butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small 668 molecule inhibitors of the severe acute respiratory syndrome coronavirus

Crystal structure of SARS-CoV-2 main protease provides a basis for design 671 of improved α-ketoamide inhibitors

CoV-2 main protease

Integrated Strategy for Lead Optimization Based on Fragment Growing: 675 The Diversity-Oriented-Target-Focused-Synthesis Approach

0: A retrosynthesis 678 workflow for metabolic engineers

Route Designer: a retrosynthetic analysis tool utilizing automated 680 retrosynthetic rule generation

A retrosynthetic analysis algorithm 682 implementation

Estimation of synthetic accessibility score of drug-like 684 molecules based on molecular complexity and fragment contributions

RASA: a rapid retrosynthesis-based scoring method for 687 the assessment of synthetic accessibility of drug-like molecules

Assessing synthetic accessibility of chemical 690 compounds using machine learning methods

A unique inhibitor binding site in ERK1/2 is associated with slow 692 binding kinetics

Chemical and computational methods for the characterization of 694 covalent reactive groups for the prospective design of irreversible inhibitors

BIreactive: A Machine-Learning Model to Estimate Covalent Warhead Reactivity

Predictor Tool for Covalent Reactivity Estimation of Acrylamides

Expanding the Armory: Predicting and Tuning Covalent Warhead 702

Targeting biomolecules with reversible covalent chemistry

Selective and reversible modification of kinase cysteines with 706 chlorofluoroacetamides

Applications of Reactive Cysteine Profiling

Arylfluorosulfate-Based Electrophiles for Covalent Protein 710 Labeling: A New Addition to the Arsenal

Covalent protein modification: the current landscape of 712 residue-specific electrophiles

New Electrophiles and Strategies for Mechanism-Based and 714

Native protein sequences are close to optimal for their structures

Crowdsourcing drug discovery for 719 pandemics

Integration, scaling, space-group assignment and post-refinement

Decision making in xia2

Data processing and analysis with the autoPROC toolbox

DIALS: implementation and evaluation of a new integration package

The XChemExplorer graphical workflow tool for routine or large-scale 729 protein-ligand structure determination

DIMPLE: a difference map pipeline for 732 the rapid screening of crystals on the beamline

A multi-crystal method for extracting obscured crystallographic states 736 from conventionally uninterpretable electron density

AceDRG: a stereochemical description generator for ligands

BUSTER version 2.10. 0. Cambridge, United Kingdom: Global Phasing 742

Oded Livnah for generously providing us recombinant ERK2. N.L. is the 746 incumbent of the Alan and Laraine Fischer Career Development Chair. N.L. would like to 747 acknowledge funding from the Israel Science Foundation

Israel Cancer Research Fund, the Israeli Ministry of Science Technology

This 750 research was supported by Nelson P. Sirotsky. N.L. is also supported by the Helen and Martin 751

Joel and Mady Dukler Fund for Cancer Research, the Estate 752

was funded in 753 part by the pearlman student-initiated research award. The SGC is a registered charity (number 754 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada 755 Foundation for Innovation

Ontario Ministry of Economic Development 758 and Innovation